SBRT for oligoprogressive disease: using the evidence to maximise the benefits

Gerard G Hanna¹, Fiona McDonald²

Affiliations

¹ Department of Oncology, Belfast Health and Social Care Trust, Belfast BT9 7AB, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK. Electronic address: g.hanna@qub.ac.uk.
² Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.

PMID: 38104574
DOI: 10.1016/S0140-6736(23)02351-6

Comment

SBRT for oligoprogressive disease: using the evidence to maximise the benefits

Gerard G Hanna et al. Lancet. 2024.

. 2024 Jan 13;403(10422):122-124.

doi: 10.1016/S0140-6736(23)02351-6. Epub 2023 Dec 14.

Authors

Gerard G Hanna¹, Fiona McDonald²

Affiliations

¹ Department of Oncology, Belfast Health and Social Care Trust, Belfast BT9 7AB, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK. Electronic address: g.hanna@qub.ac.uk.
² Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.

PMID: 38104574
DOI: 10.1016/S0140-6736(23)02351-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

GGH has received speaker fees from AstraZeneca, and travel and conference attendance support from MSD. FM has received speaker fees and advisory board honoraria from AstraZeneca.

Comment on

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN; CURB Study Group. Tsai CJ, et al. Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104577 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SBRT for oligoprogressive disease: using the evidence to maximise the benefits

Affiliations

SBRT for oligoprogressive disease: using the evidence to maximise the benefits

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical